The effect of melatonin on plasma markers of inflammation and on expression of nuclear factor-kappa beta in acetic acid-induced colitis in the rat

Digestive Diseases and Sciences

Volumn 58, Issue 11, 2013, Pages 3156-3164

  Sayyed, Hayam G ^a   Jaumdally, Rumi J ^c   Idriss, Naglaa K ^a   El Sers, Dalia A ^b   Blann, Andrew ^d  

^a Assiut University Faculty of Medicine   (Egypt)

^b Assiut University   (Egypt)

^c WALSALL HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acetic acid induced colitis; Melatonin; Nuclear factor kappa beta; Pentraxin 3

Indexed keywords

ACETIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID PEROXIDE; MELATONIN; PENTRAXIN 3; THIOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; COLON; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LONG TERM CARE; MALE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; TISSUE INJURY; ULCERATIVE COLITIS;

ACETIC ACID; ANIMALS; BIOLOGICAL MARKERS; COLITIS; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; MELATONIN; NF-KAPPA B; RATS;

EID: 84889600643     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2811-x     Document Type: Article

References (44)

1. Pandi-Perumal SR, Srinivasan V, Maestroni GJM, et al. Melatonin: nature's most versatile biological signal? FEBS J. 2006;273:2813-2838.
2. Reiter RJ, Paredes SD, Manchester LC, et al. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol. 2009;44:175-200.
3. Hardeland R, Cardinali DP, Srinivasan V, et al. Melatonin - a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93:350-384.
4. 1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res. 2001;21:85-91.
5. Mei Q, Yu JP, Xu JM, et al. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin. 2002;23:882-886.
6. Hagar HH, El-Medany A, El-Eter E, Arafa M. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol. 2007;554:69-77.
7. Mei Q, Xu JM, Xiang L, et al. Change of nitric oxide in experimental colitis and its inhibition by melatonin in vivo and in vitro. Postgrad Med J. 2005;81:667-672.
8. Li JH, Yu JP, Yu HG, et al. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005;4:185-193.
9. Mazzon E, Esposito E, Crisafulli C, et al. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res. 2006;41:363-373.
10. Marquez E, Sanchez-Fidalgo S, Calvo JR, et al. Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. J Pineal Res. 2006;40:48-55.
11. Wu F, Chakravarti S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappa B inhibition in a mouse model of chronic colitis. J Immunol. 2007;179:6988-7000.
12. Yuan H, Ji W, Wu K, Jiao JX, Sun LH, Feng YT. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol. 2006;12:4578-4581.
13. Giuseppe DN, Cecilia G, Alberico LC. The long Pentraxin PTX3: a modulator of the immuno-inflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35-40.
14. Jaillon S, Peri G, Delneste Y. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007;204:793-804.
15. Sprong T, Peri G, Neeleman C, et al. Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock. 2009;31:28-32.
16. Norata GD, Marchesi P, Pulakazhi VK, et al. Deficiency of the long pentraxin PTX-3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120:699-708.
17. Savchenko AS, Inoue A, Ohashi R, et al. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol Int. 2011;61:290-297.
18. Drew JE, Farquharson AJ, Keijer J, Barrera LN. Complex regulation of mucosal pentraxin (Mptx) revealed by discrete micro-anatomical locations in colon. Biochim Biophys Acta. 2006;1762:844-848.
19. Kawada M, Arihiro A, Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol. 2007;13:5581-5593.
20. Tahan G, Gramignoli R, Marongiu F, et al. Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig Dis Sci. 2010;56:715-720.
21. Jena G, Trivedi PP, Sandala B. Oxidative stress in ulcerative colitis: an old concept but a new concern. Free Radic Res. 2012;46:1339-1345.
22. Necefli A, Tulumoǧlu B, Giriş M, et al. The effect of melatonin on TNBS-induced colitis. Dig Dis Sci. 2006;51:1538-1545.
23. Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795-803.
24. Mylonas I, Jeschke U, Kunert-Keil C, et al. Glycodelin A is expressed differentially in normal human endometrial tissue throughout the menstrual cycle as assessed by immunohistochemistry and in situ hybridization. Fertil Steril. 2006;86:1488-1497.
25. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissue by thiobarbituric acid test. Anal Biochem. 1978;86:271-278.
26. Ellman GL. Tissue sulphydryl groups. Arch Biochem Biophys. 1959;84:70-77.
27. Márquez L, Pérez-Nievas BG, Gárate I, et al. Anti-inflammatory effects of Mangifera indica L. extract in a model of colitis. World J Gastroenterol. 2010;16:4922-4931.
28. Chojnacki C, Wisniewska-Jarosinska M, Walecka-Kapica E, et al. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol. 2011;62:327-334.
29. Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol. 2007;41:29-32.
30. Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem. 2010;17:2070-2095.
31. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double blind placebo-controlled study. Aliment Pharmacol Ther. 2005;22:927-934.
32. Nosál'ová V, Zeman M, Cerná S, Navarova J, Zakalova M. Protective effect of melatonin in acetic acid induced colitis in rats. J Pineal Res. 2007;42:364-370.
33. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
34. Hollenbach E, Vieth M, Roessner A, Neumann M, Malfertheiner P, Naumann M. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem. 2005;280:14981-14988.
35. De Vry CG, Prasad S, Komuves L, et al. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut. 2007;56:524-533.
36. CieÅlik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity. 2012;45:119-128.
37. Baruah P, Ingrid ED, Giuseppe P, et al. The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leuk Biol. 2006;80:87-95.
38. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med. 1999;27:916-921.
39. Métayer S, Seiliez I, Collin A, et al. Mechanisms through which sulfur amino acids control protein metabolism and oxidative status. J Nutr Biochem. 2008;19:207-215.
40. Cuzzocrea S, Mazzon E, Serranino I, et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res. 2001;30:1-12.
41. Szczepanik M. Melatonin and its influence on immune system. J Physiol Pharmacol. 2007;58:115-124.
42. Terry PD, Villinger F, Bubenik GA, Sitaraman SV. Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflamm Bowel Dis. 2009;15:134-140.
43. Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des. 2011;17:4372-4378.
44. Lin GJ, Huang SH, Chen SJ, Wang CH, Chang DM, Sytwu HK. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci. 2013;14:11742-11766.